GOLDEN, Colo.--(BUSINESS WIRE)--PharmaJet®, a company that strives to improve the performance and outcomes of injectables with its enabling technology, today announced that they will share their latest research results at the World Vaccine Congress – Europe on October 29, 2024 at 1:40 pm GMT. The presentation, entitled Improving Performance of Vaccines with Needle-free Technology will be presented by Nathalie Landry, Chief Scientific Officer, PharmaJet..

。。

The PharmaJet Needle-free Systems are increasingly being incorporated into clinical studies across multiple infectious disease and oncology development programs, with over 52 studies and 49 partners. “The body of evidence continues to grow on how PharmaJet’s needle-free delivery can improve the performance of prophylactic and therapeutic vaccine candidates,” said Nathalie Landry, Chief Scientific Officer, PharmaJet.

PharmaJet无针系统越来越多地被纳入多种传染病和肿瘤学发展计划的临床研究中，有52多项研究和49个合作伙伴。PharmaJet首席科学官Nathalie Landry说：“大量证据表明，PharmaJet的无针注射可以改善预防性和治疗性候选疫苗的性能。”。

“When it comes to administering vaccines and therapeutics, the important outcomes are increased immunogenicity and enhanced protection from disease. The data shows that needle-free can be expected to enhance immune responses.”.

“当涉及到疫苗和治疗时，重要的结果是提高免疫原性和增强对疾病的保护。数据显示，无针可以增强免疫反应。”。

For more information about PharmaJet visit Booth #71 at the conference or visit the website https://pharmajet.com.

有关PharmaJet的更多信息，请访问会议上的展位#71或访问网站https://pharmajet.com.

Refer to Instructions for Use to ensure safe injections and to review risks.

请参阅使用说明，以确保安全注射并审查风险。

About PharmaJet

关于PharmaJet

The PharmaJet mission is to improve the performance and outcomes of injectables with our enabling technology that better activates the immune system. We are committed to helping our partners realize their research and commercialization goals while making an impact on public health. PharmaJet Precision Delivery Systems™ can improve vaccine effectiveness, allow for a preferred patient and caregiver experience, and offer a proven path to commercialization.

PharmaJet的使命是通过我们的使能技术更好地激活免疫系统，提高注射剂的性能和效果。我们致力于帮助我们的合作伙伴实现其研究和商业化目标，同时对公共卫生产生影响。PharmaJet Precision Delivery Systems™可以提高疫苗的有效性，提供首选的患者和护理人员体验，并为商业化提供一条行之有效的途径。

They are also safe, fast, and easy-to-use. The Stratis® System has U.S. FDA 510(k) marketing clearance, CE Mark, and WHO PQS certification to deliver medications and vaccines either intramuscularly or subcutaneously. The Tropis® System has CE Mark and WHO PQS certification for intradermal injections.

它们也安全、快速且易于使用。Stratis®系统具有美国FDA 510（k）上市许可证、CE标志和WHO PQS认证，可肌肉注射或皮下注射药物和疫苗。Tropis®系统具有CE标志和WHO皮内注射PQS认证。

They are both commercially available for global immunization programs. For more information or if you are interested in partnering with PharmaJet to improve the impact of your novel development program, visit https://pharmajet.com or contact PharmaJet here. Follow us on LinkedIn..

它们都可用于全球免疫计划。有关更多信息，或者如果您有兴趣与PharmaJet合作以提高您的新型开发计划的影响力，请访问https://pharmajet.com或者在这里联系PharmaJet。在LinkedIn上关注我们。。